EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Potential of Heat Shock Protein 90 Inhibitors, Geldanamycin, and Analog Compounds in Precision Cancer Therapy

Atta Mohammed Alzebari, Amjad Mahmood Qadir, Mahmood Sherzad Rafaat, Abbas Salihi

BioMed Target Journal · 2023

DOI: 10.59786/bmtj.122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioMed Target Journal, 2023. Verfasst von Atta Mohammed Alzebari und 3 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heat shock protein (HSP90) is a molecular chaperone involved in numerous physiological processes. The primary role of this is to assist in the process of protein folding and to restore misfolded proteins to their correct shape. Chaperones additionally inhibit protein breakdown and aggregation. HSP90 inhibitors possess a notable characteristic of obstructing many cancer-causing pathways by facilitating the breakdown of numerous oncogenic client proteins. Targeting HSP90 therapeutics has been recognized as a viable approach for treating cancer and inflammatory-associated disorders in clinical studies involving different forms of cancer. Inhibition of HSP90 using natural, synthetic, and semi-synthetic chemicals has shown encouraging outcomes. HSP90 inhibitors have been extracted from several fungi, bacteria, and plant species. These naturally occurring chemicals play a crucial function in regulating HSP90 activity and can be utilized to develop innovative semi-synthetic or synthetic inhibitors. Over 120 clinical trials have been carried out to evaluate the effectiveness of HSP90 inhibitors as a supplementary therapy for different types of tumor cells. Presently, ongoing research is being carried out to acquire an understanding of innovative and more efficacious methods for treating cancer. Continuing in this research approach, we aim to investigate the discovery, biosynthesis, mechanism of action, and biological features of geldanamycin and its analogs.

Zitieren

APA

Alzebari, A. M., Qadir, A. M., Rafaat, M. S., & Salihi, A. (2023). Therapeutic Potential of Heat Shock Protein 90 Inhibitors, Geldanamycin, and Analog Compounds in Precision Cancer Therapy. BioMed Target Journal. https://doi.org/10.59786/bmtj.122

Vancouver

Alzebari AM, Qadir AM, Rafaat MS, Salihi A. Therapeutic Potential of Heat Shock Protein 90 Inhibitors, Geldanamycin, and Analog Compounds in Precision Cancer Therapy. BioMed Target Journal. 2023. doi:10.59786/bmtj.122

BibTeX
@article{Alzebari2023,
  author = {Alzebari, Atta Mohammed and Qadir, Amjad Mahmood and Rafaat, Mahmood Sherzad and Salihi, Abbas},
  title = {Therapeutic Potential of Heat Shock Protein 90 Inhibitors, Geldanamycin, and Analog Compounds in Precision Cancer Therapy},
  journal = {BioMed Target Journal},
  year = {2023},
  doi = {10.59786/bmtj.122}
}
Kostenlos starten →